Background: One of the goals of DM management is to achieve glycemic control to prevent or delay acute and chronic complications. ADA recommends planned visits through team-based approach to improve delivery of DM care. AHN Diabetes Academy (DA) is a 12-week team-based care program for patients w/A1C >9%, T1DM, or worsening complications.

Objective: Determine if patients who participated in DA have sustained glucose control at 1 year.

Method: Compare A1C at the start, end of DA and at 1-year follow-up.

Results: A total of 221 patients were enrolled from 9/26/16 to 10/22/17. Seventy-seven % had T2DM, 21% had T1, 2% had T1.5. Thirty-nine were lost to follow-up or did not have A1C at 1 year, allowing data analysis for 182 patients at 1 year. Mean A1C decreased significantly from 9.4 to 7.7% for all patients from enrollment to discharge; A1C at 1-year follow-up was 7.8%, unchanged from discharge showing sustained glycemic control at 1 year (Figure). When DM subtypes were analyzed, mean A1C decreased significantly for T1 and T2 from enrollment to discharge, no statistical change in T1.5 (likely due to small sample size). No significant change in mean A1C from discharge to 1 year for all subtypes.

Conclusion: AHN DA achieved sustained glycemic control at 1 year after completion of 12-week team-based program. Teaching Points: Team based care attains sustained glycemic control at 1 year, is effective for T1 and T2DM, and benefits those at high risk for acute and chronic complications.


J. Violago: Stock/Shareholder; Spouse/Partner; Abbott, AbbVie Inc., Cardinal Health, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. P. Bononi: Other Relationship; Self; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at